- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-SPARC
SPARC Polyclonal Antibody for WB, IHC, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, porc, rat, souris et plus (1)
Applications
WB, IF, IHC, CoIP, ELISA
Conjugaison
Non conjugué
N° de cat : 15274-1-AP
Synonymes
Galerie de données de validation
Applications testées
Résultats positifs en WB | cellules A375, cellules ROS1728, tissu placentaire humain, tissu testiculaire humain |
Résultats positifs en IHC | tissu de cancer de l'estomac humain, il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
Dilution recommandée
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:1000-1:8000 |
Immunohistochimie (IHC) | IHC : 1:1000-1:4000 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Applications publiées
WB | See 28 publications below |
IHC | See 9 publications below |
IF | See 7 publications below |
CoIP | See 1 publications below |
Informations sur le produit
15274-1-AP cible SPARC dans les applications de WB, IF, IHC, CoIP, ELISA et montre une réactivité avec des échantillons Humain, porc, rat, souris
Réactivité | Humain, porc, rat, souris |
Réactivité citée | rat, Humain, souris, cerf Sika |
Hôte / Isotype | Lapin / IgG |
Clonalité | Polyclonal |
Type | Anticorps |
Immunogène | SPARC Protéine recombinante Ag7390 |
Nom complet | secreted protein, acidic, cysteine-rich (osteonectin) |
Masse moléculaire calculée | 35 kDa |
Poids moléculaire observé | 35-43 kDa |
Numéro d’acquisition GenBank | BC004974 |
Symbole du gène | SPARC |
Identification du gène (NCBI) | 6678 |
Conjugaison | Non conjugué |
Forme | Liquide |
Méthode de purification | Purification par affinité contre l'antigène |
Tampon de stockage | PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3 |
Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
Secreted Protein Acidic And Cysteine Rich (SPARC), also known as osteonectin or basement-membrane protein 40 (BM-40), is a secreted protein essential in the calcification of bone.
What is the molecular weight of SPARC?
The calculated molecular mass of SPARC is 35 kDa. SPARC is a glycoprotein consisting of 303 amino acids in the cytoplasm and 286 amino acids after the signal sequence is cleaved in secretion.
Where is SPARC expressed?
Osteoblasts secrete SPARC during bone formation, with high levels found in immature bone compared to mature bone that is in homeostasis (PMID: 2440898). SPARC is also secreted in adult mineralized tissues that have high turnover, such as osteoid and dentin, by cells other than osteoblasts. This includes bone marrow progenitor cells and hypertrophic chondrocytes but also endothelial cells and fibroblasts.
Though previously described as being exclusively expressed in mineralized tissue, it is now understood that SPARC is more widely expressed and is associated with high levels of collagen deposition, found in the extracellular matrix (ECM) of a number of tissues.
What is the function of SPARC?
SPARC contains both a collagen-binding domain and a hydroxyapatite (HA) binding region, so is thought to enhance mineralization by binding both collagen and HA crystals, causing the release of calcium ions (PMID: 26851678).
SPARC can bind to a number of different ECM proteins, particularly collagen, and may even influence the assembly of these proteins (PMID: 19798598). It is known to regulate interactions between cells and the ECM, meaning it plays a role in many important processes such as cell migration and proliferation.
What diseases are associated with SPARC?
Overexpression of SPARC has been identified in a number of different types of cancers (PMID: 18849185), although its role may vary. For example, in neuroblastomas SPARC acts as a suppressor but in gliomas, it causes greater invasion of the tumor. Mutations in SPARC can also lead to Osteogenesis Imperfecta, also known as brittle bone disease (PMID: 26027498).
Protocole
Product Specific Protocols | |
---|---|
WB protocol for SPARC antibody 15274-1-AP | Download protocol |
IHC protocol for SPARC antibody 15274-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
ACS Appl Mater Interfaces Evidence for Delivery of Abraxane via a Denatured-Albumin Transport System. | ||
Theranostics A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. | ||
Int J Cancer Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression | ||